Reports and Insights clinical trial study report, “Antibody cocktail clinical trial study report and future assessment for antibody cocktail market demand, market size, market share, 2020 to 2028" provides an outline for antibody cocktail clinical trial study on coronavirus disease 2019 (COVID-19). This clinical trial study provides relevant data associated with trials on coronavirus disease 2019 (COVID-19).
The study report includes a top line data with respect to number of trials and their standard enrollment in top countries conducted globally. The study provides coverage of malady clinical trials by region, country, different phases, segments and trial status along with end points status and sponsor type. Furthermore, report also provides leading drugs for currently active trials with qualitative data.
Reports and Insights clinical trial study reports are prepared using Reports and Insights existing and research proprietary database, pharma database, and pre-clinical trials database. Clinical trials are gathered and grouped from various available registries in clinical trials, journals, news, and other authentic sources available worldwide. Clinical trials database includes synchronized updates through internal dynamic processes.
The world has been through immensely challenging times in the past year due to the sudden strike of Coronavirus disease 2019 (COVID-19), caused by a novel acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By virtue of this fact, there have also been constant efforts to develop therapeutics and vaccines in retaliation to the COVID-19 global pandemic emerging at an unconventional pace and scale. Among all the proceedings for the development of suitable vaccines, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) examined two entirely potent, nullifying monoclonal antibodies combating against severe respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, utilized in a blended cocktail, known as REGN-COV2, to mitigate the risk of the outgrowth of mutant virus.
The antibodies used in the antibody cocktail - REGN10933 and REGN10987, are selected after screening thousands of options. One of the antibodies came from a human survivor of COVID-19, and the other one is from a mouse that has been genetically designed to have a human immune system. The coronavirus spike protein had been injected in the mouse, and then its antibody was obscured and replicated.
Although the experimental antibody cocktail is yet going through tests and trials, the therapy has been approved for emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
The pharmaceutical and commercialized success of monoclonal antibodies (mAbs) has encouraged and provided a vision to novel innovative approaches intended at enhancing their efficacy and widening their pertinence. Among these, cocktails of recombinant human monoclonal antibodies are a rational further step owing to the fact that they combine the technological enhancements made in the field of antibody technology with the idea that the elements of polyclonal-antibody preparations act in unison in order to strive and engage catalyst functions.
The monoclonal antibody cocktail, developed by Regeneron Pharmaceuticals, Inc., is yet undergoing phase 3 human trials, although it successfully received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). As per the president and chief executive officer of Regeneron, Leonard S. Schleifer, the approval of the antibody cocktail for emergency use by the FDA is a crucial step in the combat against COVID-19, as patients with high-risk in the United States are going to have access to assuring therapy initially in the path of their infection.
It is worth noting that in the month of October 2020, the former U.S. President Donald Trump received a preliminary antibody treatment after a test showed that he got affected with SARS-CoV-2. Around that time, he allegedly had moderate symptoms of COVID-19, involving congestion and fever. Regeneron, who developed the cocktail, a week earlier showed preliminary data from its progressive clinical trial in masses who tested positive for COVID-19 but were asymptomatic or, in the most extreme cases, had mild symptoms—a bunch of people who were resembling the president’s condition. The treatment surfaced no severe safety concerns, as well as diminished viral load and lessened symptomatic disease in patients who did not have COVID-19 antibodies at the start of the trial. It is yet uncertain whether the antibody cocktail treatment can prevent COVID-19 infection but there are chances that it might.
Regeneron’s developed casirivimab and imdevimab antibody cocktail, known as REGN-COV2 or REGEN-COV2, is a cocktail made of two fully-humanized monoclonal antibodies that obligate to different regions of the SARS-CoV-2 spike protein. REGN10933 and REGN10987 are the two humanized monoclonal antibodies used in the antibody cocktail that is pinned down after filtering thousands of options.
One of the two antibodies used in the cocktail came from a human survivor of COVID-19, and the other one is selected from a mouse that has been genetically designed to have a human immune system. The coronavirus spike protein had been injected into the mouse, and then its antibody was obscured and replicated.
Apart from that, a different protocol was established to treat symptomatic rabies in rodents using a cocktail of two effective neutralizing human monoclonal antibodies is mAbs RVC20 and RVC58. Rabies is a relatively invariably lethal disease and it can be treated and cured in rabiesâ€exposed patients by the administration of postâ€exposure prophylaxis (PEP), at the right time, joining immunoglobulins and the rabies vaccine. The monoclonal antibodies RVC20 and RVC58 cocktail signify remarkable feasibility to establish a potent medical cure of brain infection caused by rabies virus, thereby escalating survival rate and healing neurological symptoms.
Regeneron Pharmaceuticals, Inc. recently reported that the U.S. Department of Defense (DOD) and the Department of Health and Human Services (HHS) are going to buy additional supplies of the imdevimab and casirivimab antibody cocktail for usage in non-hospitalized COVID-19 patients. As per the new agreement, the government is going to purchase all complete doses of the casirivimab and imdevimab antibody cocktail supplied by June 30, 2021, up to 1.25 million doses.
Eli Lilly, an American pharmaceutical company, is also claiming its monoclonal antibody prevented COVID-19 infections in the staff and nursing home residents in a clinical trial. The antibody, bamlanivimab, developed by Eli Lilly was authorized for emergency usage by the Food and Drug Administration in treating patients with COVID-19 who are prone to more severe disease. Lilly trusts its antibody could be an alternative not just to operate and cure COVID-19 but to aid avert it in defined circumstances.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug, known as AZD7442, hoping that it could be utilized as a preventive measure to treat COVID-19 infection in people who are at-risk for up to 12 months. The international Phase III clinical trial is supposed to select a total of 5,000 people across countries in the US and Europe in order to examine the effectiveness and safety of the antibody cocktail.
To learn more about this report, request a free sample copy
• Report Overview
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Ongoing Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Drug Overdose Therapeutics Clinical Trials
• Prominent Drugs
• Clinical Trial Profile Snapshots
• Invivo Efficiency Assessment (Clinical, Pre-clinical & Pre-Marketing Forecast)
• Monoclonal Antibodies Assessment (Casirivimab and Imdevimab) (Clinical, Pre-clinical & Pre Marketing Forecast)
• Prophylactic Study
• Animal Model Analysis (Macaca mulatta, mice & Hamster)
• Mehtods Involved (Histopathology, Virus RNA Sequencing, RNAaeq Data Analysis)
• Administration Timeline Analysis (Age, Sex & Other Factors)
• Adverse Effects and Limitation Assessment
• Clinical Phase Analysis (Phase 1-3 and Post-Approval & Pre-marketing)
• Viral Load Reduction Analysis
• Intervention Assessment
• Safety Evaluation Study
• Comparitive Analysis
• Cohort Study
• Antibody Cocktail Market
o Executive Summary
o Market Taxonomy
• Global Antibody Cocktail Market Size and Forecast, 2020–2028
o Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
• Global Antibody Cocktail Market Dynamics
• Key Regulations
• Porter’s Five Forces Model
• Global Antibody Cocktail Market, By Products
• Global Antibody Cocktail Market, By Indication
• Global Antibody Cocktail Market, By Age
• Global Antibody Cocktail Market, By Region
o North America
o Latin America
o Asia Pacific
o Middle East
o Market Strategy
• Competitive Landscape
o Prominent Key Players Company Profiles
o Key Players Strategies
o Key Developments
The antibody cocktail market is estimated to reach at a value of US$ *** Mn by the end of 2022 and expected to reach at a value of US$ *** Mn by 2030 with a significant CAGR of ***%.
The base year for the report is 2021 in antibody cocktail market.
Regeneron’s developed casirivimab and imdevimab antibody cocktail, known as REGN-COV2 or REGEN-COV2. REGN10933 and REGN10987 are the two humanized monoclonal antibodies used in the antibody cocktail that is pinned down after filtering thousands of options.
Regeneron Pharmaceuticals, Inc., Eli Lilly, and AstraZeneca are top companies which are participating in antibody cocktail clinical trials